celecoxib oral

P1, N=200, Not yet recruiting, Shandong Suncadia Medicine Co., Ltd.

P1, N=6, Active, not recruiting, HonorHealth Research Institute | Recruiting --> Active, not recruiting | N=18 --> 6 | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Jun 2025 --> Jun 2026

Rats were administered OANG (high/low dose) intra-articularly, with celecoxib as a positive control...Furthermore, OANG ameliorated hippocampal oxidative stress and inflammation (decreased Cleaved caspase-3, Malondialdehyde; increased IL-10). Network pharmacology and docking suggested the involvement of peroxisome proliferator-activated receptor gamma, mitogen-activated protein kinase 3, prostaglandin-endoperoxide synthase 2, and pathways such as estrogen signaling and cyclic adenosine monophosphate signaling.

This study investigates the in vitro antitumor properties and mechanism of action of novel vicinal diaryl-substituted heterocyclic COX-2 inhibitors, with a focus on VA1213, in comparison to celecoxib, a widely marketed COX-2 inhibitor known for its off-target effects...Its ability to interfere with multiple cancer-associated signaling pathways and reduce tumor cell aggressiveness underscores its potential as a promising therapeutic candidate. Further in vivo studies are warranted to confirm its efficacy and assess potential off-target effects.

Docking analysis results demonstrated that compounds 1, 2, 4, and 5 had the capacity to occupy the catalytic domain of COX-2 enzymes, exhibiting analogous binding conformations to those observed with the selective COX-2 inhibitor celecoxib. All these findings implied that these di/trinormonoterpenoid glucosides derived from PC possess promising characteristics for development as novel COX-2-targeted therapeutic agents.

P1, N=15, Recruiting, C17 Council | Not yet recruiting --> Recruiting | Trial completion date: Sep 2032 --> Dec 2032 | Trial primary completion date: Sep 2030 --> Dec 2030

P2, N=4, Completed, Leidos Life Sciences | Active, not recruiting --> Completed | N=2000 --> 4

A nuclear factor-kappa B (NF-κB) inhibitor, BAY11-7082, and a cyclooxygenase 2 (COX2) inhibitor, celecoxib, significantly inhibited PGE2 secretion, indicating that NF-κB and COX2 played a crucial role in reovirus-induced PGE2 production. These results indicate that reovirus replication in tumor cells is important for reovirus-induced PGE2 production. Attention should be paid to possible PGE2 production in tumors following reovirus treatment.

P1/2, N=80, Recruiting, Tanta University | Not yet recruiting --> Recruiting

Observational studies have associated use of aspirin and selective cyclooxygenase inhibitors with decreased recurrence and improved survival in patients with colon cancer...This was a post hoc analysis of the phase 3 Cancer and Leukemia Group B (now Alliance)/Southwest Oncology Group 80702 randomized clinical trial (2010-2015) assessing adjuvant celecoxib vs placebo and 3 vs 6 months of adjuvant 5-fluorouracil, leucovorin, and oxaliplatin for stage III colon cancer...The findings of this post hoc analysis suggest that ctDNA status has the potential to inform clinical decision-making among patients with stage III colon cancer who should consider adjuvant celecoxib in addition to conventional chemotherapy. ClinicalTrials.gov Identifier: NCT01150045.

P1/2, N=80, Not yet recruiting, Tanta University

P2, N=270, Recruiting, Sun Yat-sen University | N=150 --> 270